Therapeutic advances in gastroenterology
Cure8 research brief
Why This Matters
Some people with IBD who have respiratory symptoms may have lasting problems with lung gas exchange even when their bowel disease is inactive. Knowing this can prompt clinicians to check lung function rather than assuming symptoms are unrelated.
Who Should Pay Attention
Adults with IBD who develop respiratory symptoms, gastroenterologists, pulmonologists, and researchers studying extraintestinal manifestations of IBD.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The study followed consecutive IBD patients who had respiratory symptoms and underwent pulmonary function tests and chest CT imaging. Of 75 patients with DLCO measurements, 12 had chronic DLCO reduction (median ~63% predicted) over a median 26.9 months. Most had mild or inactive IBD and were receiving biologic therapy.
Imaging findings were mild and did not clearly explain the diffusion impairment. What this suggests: In symptomatic IBD patients, chronic impairment in gas exchange can persist independently of intestinal disease activity; clinicians may consider pulmonary function testing when respiratory symptoms are present.
Study limits and next steps: This is a single-center cohort of symptomatic patients, so the 16% prevalence applies to that selected group. The abstract-level report does not provide detailed methods, full imaging or medication breakdowns, or mechanistic explanations; further multicenter studies would help define causes and management.
Keep In Mind
This report is based on an abstract-level summary from a single-center prospective study of symptomatic patients; results may not generalize to all people with IBD. The study notes patients were largely on biologics and had mild or inactive bowel disease; the abstract does not establish cause or treatment implications.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationTherapeutic advances in gastroenterology
AuthorsHugo Maisonneuve, Benedicte Caron, Anne Guillaumot +7 more
InstitutionDépartement de Pneumologie, CHRU de Nancy, Pôle des Spécialités Médicales, Université de Lorraine, Nancy, France.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 3, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: HM, MP, FC, DS and AC have no conflicts of interest to declare. BRB declares fees for lectures and advisory board participation from Sanofi, AstraZeneca, and Chiesi, and travel and accommodation support for scientific meetings from Asten Santé and Vitalaire. BC declares fees from AbbVie, Celltrion Healthcar, Janssen and Pfizer, honoraria from AbbVie, Amgen, Celltrion Healthcare, Janssen, Lilly, Nordic Pharma, Pfizer and Takeda. AG declares honoraria from Boehringer-Ingelheim and support for attending meetings from Boehringer-Ingelheim, Asten, Chiesi, CSL Behring and Zambon. LPB declares fees from Abbvie et al., LPB declares fees from Abbvie, Abivax, Adacyte, Alimentiv, Alfasigma, Amgen, Apini, Banook, BMS, Celltrion, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Iterative Health, Janssen, Lilly, LifeMine, Medac, Morphic, MSD, Nordic Pharma, Novartis, Oncodesign Precision Medicine, ONO Pharma, OSE Immunotherapeuthics, Par’ Immune, Pfizer, Prometheus, Roche, Roivant, Samsung, Sandoz, Sanofi, Sorriso, Spyre, Takeda, Teva, ThirtyfiveBio, Tillots, Vectivbio, Vedanta, Ventyx. LPB declares honoraria from Abbvie, Alfasigma, Amgen, Biogen, Celltrion, Ferring, Galapagos, Genentech, Gilead, Iterative Health, Janssen, Lilly, Medac, MSD, Nordic Pharma, Pfizer, Sandoz, Takeda, Tillots. SV declares honoraria from Amgen, MSD France, Boehringer-Ingelmheim and AstraZeneca, support for attending meetings from MSD France and SOS oxygene.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Pancreatic Hyperenzymemia in Inflammatory Bowel Disease: Clinical Characterization and Outcomes from the European PANDORA Registry.
Elevated pancreatic enzymes are relatively common in IBD and can reflect very different conditions (benign asymptomatic elevations, pancreatitis variants, or autoimmune pancreatitis). Recognizing phenotype-specific...
Arthralgia, EIMs Linked to Risk for IBD-Related Arthritis in Crohn Disease
Arthralgia and other extraintestinal symptoms may signal higher risk of developing peripheral arthritis in people with Crohn disease. Recognizing early joint pain could prompt closer monitoring or earlier rheumatology...
Rare colorectal manifestations of pediatric gastrointestinal lymphoma: a systematic review of clinical spectrum and surgical implications.
Colorectal lymphoma in children can mimic IBD flares or cause surgical emergencies; recognizing this can prevent inappropriate escalation of immunosuppression and speed correct diagnosis and treatment.